Case Overview: Bayer's Monsanto has proposed a $7.25 billion nationwide class settlement to resolve claims that its Roundup herbicide caused non-Hodgkin lymphoma, establishing a long-term compensation program lasting up to 21 years.

Consumers Affected: Current and certain future claimants who allege Roundup exposure caused non-Hodgkin lymphoma (NHL)

Court: To be determined pending settlement approval proceedings

Bayer's Monsanto Proposes $7.25 Billion Roundup Settlement for Non-Hodgkin Lymphoma Claimants

Bayer's Monsanto has put forward a proposed $7.25 billion nationwide class settlement aimed at resolving years of litigation over allegations that its widely used Roundup herbicide caused non-Hodgkin lymphoma. According to a recent report on the proposed settlement, the proposal would establish a structured, long-term claims program running as long as 21 years — covering not only those who have already filed suit, but potentially certain future claimants as well.

The announcement marks one of the more significant developments in what has become one of the largest mass tort proceedings in recent U.S. history.

Settlement Would Establish Decades-Long Claims Program

Under the proposed framework, the $7.25 billion fund would be used to compensate current plaintiffs who allege that exposure to Roundup's active ingredient, glyphosate, caused them to develop non-Hodgkin lymphoma — a cancer of the lymphatic system.

The proposal is notable for its extended timeline. Rather than a one-time payout, the structure would fund a claims program lasting up to 21 years, a design that appears intended to address both existing lawsuits and claims from individuals who may be diagnosed in the future after a history of Roundup exposure.

If approved, the settlement could provide a path to compensation for tens of thousands of claimants who may be eligible to participate — though eligibility determinations would ultimately depend on the specific terms of any final agreement and the review process established by the program.

The Underlying Allegations: Glyphosate and Cancer Risk

The Roundup litigation centers on glyphosate, the herbicide's primary active ingredient, which has been the subject of significant scientific and regulatory debate for more than a decade. Plaintiffs in these cases allege that long-term exposure to Roundup caused them to develop non-Hodgkin lymphoma — and that Monsanto knew, or should have known, about the potential cancer risks and failed to adequately warn users.

In 2015, the International Agency for Research on Cancer (IARC), a division of the World Health Organization, classified glyphosate as "probably carcinogenic to humans," a finding that has been central to the litigation. The U.S. Environmental Protection Agency, however, has maintained that glyphosate is unlikely to be carcinogenic when used as directed — a point Bayer has repeatedly cited in its defense.

Roundup has been one of the most widely used herbicides in the world, applied extensively in agricultural settings as well as by homeowners and landscaping professionals. That broad exposure base has contributed to the scale of the litigation, with hundreds of thousands of individuals having filed or registered claims alleging injury.

A Long Road to Resolution

Bayer acquired Monsanto in 2018 for approximately $63 billion — and almost immediately inherited the mounting Roundup litigation. The company has faced a series of high-profile trial losses, including several jury verdicts awarding substantial damages to individual plaintiffs, before those awards were later reduced or overturned on appeal.

Bayer has attempted to reach a comprehensive resolution before. In 2020, the company announced an approximately $10 billion settlement framework, though that effort was complicated by legal challenges and did not resolve all pending claims. The current $7.25 billion proposal represents the company's most recent attempt to bring the litigation to a close.

The scope of the proposed 21-year program suggests Bayer is seeking finality not just for current cases but for a future wave of potential claimants — a structure that, if approved, could significantly limit the company's long-term legal exposure.

What This Means for Potential Claimants

Individuals who believe they may have developed non-Hodgkin lymphoma following prolonged exposure to Roundup may want to monitor developments in this litigation closely. If the proposed settlement receives court approval, there could be a defined process for eligible claimants to seek compensation through the program.

Those with potential claims are generally encouraged to consult with a qualified attorney to understand their options and any applicable deadlines, as statutes of limitations can vary by state and individual circumstance.

Related Cases

• PFAS Lawsuits: What You Need to Know About Forever Chemical Litigation
• Paraquat Lawsuit: Herbicide Linked to Parkinson's Disease Claims
• Camp Lejeune Water Contamination Claims

Lawsuit: In re: Roundup Products Liability Litigation (multi-district proceedings)

Case Number: MDL No. 2741

Court: U.S. District Court, Northern District of California

Settlement Proposal Announced: February 2026

Proposed Settlement Amount: $7.25 billion

Have you or someone you know used Roundup and been diagnosed with non-Hodgkin lymphoma? Share your experience in the comments below.

InjuryClaims.com reports on class action lawsuits and legal developments for informational purposes only. Nothing in this article constitutes legal advice. Readers should consult a licensed attorney regarding their individual circumstances.